BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lines KE, Stevenson M, Thakker RV. Animal models of pituitary neoplasia. Mol Cell Endocrinol 2016;421:68-81. [PMID: 26320859 DOI: 10.1016/j.mce.2015.08.024] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Zhou J, Hu Y, Zhu W, Nie C, Zhao W, Faje AT, Labelle KE, Swearingen B, Lee H, Hedley-whyte ET, Zhang X, Jones PS, Miller KK, Klibanski A, Zhou Y, Soberman RJ. Sprouting Angiogenesis in Human Pituitary Adenomas. Front Oncol 2022;12:875219. [DOI: 10.3389/fonc.2022.875219] [Reference Citation Analysis]
2 Recouvreux MV, Faraoni EY, Camilletti MA, Ratner L, Abeledo-Machado A, Rulli SB, Díaz-Torga G. Sex differences in the pituitary TGFβ1 system: The role of TGFβ1 in prolactinoma development. Front Neuroendocrinol 2018;50:118-22. [PMID: 29074127 DOI: 10.1016/j.yfrne.2017.10.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
3 D'Angelo D, De Martino M, Arra C, Fusco A. Emerging Role of USP8, HMGA, and Non-Coding RNAs in Pituitary Tumorigenesis. Cancers (Basel) 2019;11:E1302. [PMID: 31487906 DOI: 10.3390/cancers11091302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Lines KE, Vas Nunes RP, Frost M, Yates CJ, Stevenson M, Thakker RV. A MEN1 pancreatic neuroendocrine tumour mouse model under temporal control. Endocr Connect 2017;6:232-42. [PMID: 28420716 DOI: 10.1530/EC-17-0040] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
5 Mollard P, Schaeffer M. Imaging endocrinology in animal models of endocrine disease. Best Practice & Research Clinical Endocrinology & Metabolism 2018;32:317-28. [DOI: 10.1016/j.beem.2018.03.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Camilletti MA, Abeledo-Machado A, Perez PA, Faraoni EY, De Fino F, Rulli SB, Ferraris J, Pisera D, Gutierrez S, Thomas P, Díaz-Torga G. mPRs represent a novel target for PRL inhibition in experimental prolactinomas. Endocr Relat Cancer 2019;26:497-510. [PMID: 30856609 DOI: 10.1530/ERC-18-0409] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
7 Gahete MD, Jimenez-Vacas JM, Alors-Perez E, Herrero-Aguayo V, Fuentes-Fayos AC, Pedraza-Arevalo S, Castaño JP, Luque RM. Mouse models in endocrine tumors. J Endocrinol 2018:JOE-18-0571. [PMID: 30475226 DOI: 10.1530/JOE-18-0571] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
8 Carreno G, Gonzalez-Meljem JM, Haston S, Martinez-Barbera JP. Stem cells and their role in pituitary tumorigenesis. Mol Cell Endocrinol 2017;445:27-34. [PMID: 27720895 DOI: 10.1016/j.mce.2016.10.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
9 Vankelecom H, Roose H. The Stem Cell Connection of Pituitary Tumors. Front Endocrinol (Lausanne) 2017;8:339. [PMID: 29255445 DOI: 10.3389/fendo.2017.00339] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
10 Chen R, Duan J, Li L, Ma Q, Sun Q, Ma J, Li C, Zhou X, Chen H, Jing Y, Zhao S, Wu X, Zhang H. mTOR promotes pituitary tumor development through activation of PTTG1. Oncogene 2017;36:979-88. [PMID: 27524416 DOI: 10.1038/onc.2016.264] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
11 Gaudenzi G, Albertelli M, Dicitore A, Würth R, Gatto F, Barbieri F, Cotelli F, Florio T, Ferone D, Persani L, Vitale G. Patient-derived xenograft in zebrafish embryos: a new platform for translational research in neuroendocrine tumors. Endocrine 2017;57:214-9. [PMID: 27481363 DOI: 10.1007/s12020-016-1048-9] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 7.5] [Reference Citation Analysis]
12 Sun SW, Fang XM, Li YF, Wang QB, Li YX. Expression and clinical significance of EGR-1 and PTEN in the pituitary tumors of elderly patients. Oncol Lett 2017;14:2165-9. [PMID: 28789441 DOI: 10.3892/ol.2017.6375] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
13 Melmed S, Kaiser UB, Lopes MB, Bertherat J, Syro LV, Raverot G, Reincke M, Johannsson G, Beckers A, Fleseriu M, Giustina A, Wass JAH, Ho KKY. Clinical Biology of the Pituitary Adenoma. Endocr Rev 2022:bnac010. [PMID: 35395078 DOI: 10.1210/endrev/bnac010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Shariq OA, Lines KE. Epigenetic dysregulation in pituitary tumors. International Journal of Endocrine Oncology 2019;6:IJE19. [DOI: 10.2217/ije-2019-0006] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Dai C, Liang S, Sun B, Kang J. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas. Front Endocrinol (Lausanne) 2020;11:608422. [PMID: 33362722 DOI: 10.3389/fendo.2020.608422] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]